QUESTION
In pregnant women with hypertensive disorders between 34+0 and 36+6 weeks of gestation, does expectant management (aiming to prolong pregnancy until 37 weeks of gestation) compared to immediate delivery, reduce risks of adverse maternal and neonatal outcomes? METHODS  Design: Randomized controlled trial  Allocation: Randomization was via a web-based system using block randomization with variable (range 2-4) block size and was stratified by center. Allocation was 1:1.  Blinding: Participants, clinicians and outcome assessors were not blinded to the treatment allocation.  Follow-up period: Maternal data were collected until final hospital discharge and at 6 weeks following delivery. Neonatal outcome data were collected until final discharge of the neonate from hospital.  Setting: 51 maternity centers, of which seven were academic centers and 44 were non-academic hospitals in the Netherlands, between March 2009 and February 2013.  Patients: Pregnant women between 34+0 and 36+6 weeks of gestation (by ultrasound scan) were eligible to participate in the trial if they had a non-severe hypertensive disorder: gestational hypertension, pre-eclampsia, deteriorating preexisting hypertension or superimposed pre-eclampsia. Exclusion criteria were: severe hypertension, severe proteinuria, oliguria, HELLP syndrome, pulmonary oedema or cyanosis; non-reassuring fetal heart trace or reversed end diastolic flow; maternal or fetal comorbidity that would have affected management or treatment effect; ruptured membranes or other condition the attending clinician judged that prolongation of pregnancy was contraindicated. Multiple births were included.  Intervention: Women were assigned to either immediate delivery or expectant management, with delivery planned at 37 weeks of gestation. In those assigned to immediate delivery, labour was induced. Women in whom the attending clinician considered that either induction of labour or vaginal delivery was contraindicated were delivered by caesarean section. Those who were assigned to expectant management were monitored either in outpatient clinics or as inpatients, depending on their condition. Monitoring was performed according to the local guidance, but incorporated, as a minimum, regular blood pressure monitoring, twice weekly screening for proteinuria and fetal heart rate monitoring and assessment of fetal movements. Women for whom prolongation of pregnancy was contraindicated were delivered before 37 weeks of gestation. Anti-hypertensive treatment was given according to national guidelines. In the expectant monitoring group, 36% of women were delivered before 37 weeks of gestation because of concerns about maternal or fetal wellbeing. HELLP syndrome, eclampsia and placental abruption were each more common in the expectantly managed women, but numbers of all adverse outcomes were small and differences did not reach statistical significance. There were no maternal deaths in either group. The primary neonatal outcome occurred was significantly increased in the immediate delivery group compared the expectant monitoring group, yielding a number needed to harm of 25. Admission to a neonatal unit, transient tachypnea of the newborn were also more common in the immediate delivery group, with numbers needed to harm of 27 and 25 respectively. Post-hoc analysis showed a higher risk of overall neonatal morbidity in the immediate delivery group.
CONCLUSION
The authors conclude that, in women with non-severe hypertensive disorders at 34+0 to 36+6 weeks of gestation, whilst fewer adverse maternal outcomes were seen with immediate delivery than with expectant management, the risk for the neonate of developing respiratory distress syndrome was significantly increased. In view of the increased risk to the infant, they concluded that routine immediate delivery is not justified and expectant monitoring is reasonable until the woman's clinical condition deteriorates COMMENTARY, limited to 500 words Hypertensive disorders are common complications of pregnancy with associated maternal and infant risks. In severe hypertensive disorders beyond 34 weeks gestation, risks of prolonging pregnancy outweigh those of early delivery. For pregnancies complicated by severe hypertension before 34 weeks, risks of prematurity may warrant cautious monitoring and attempts to delay delivery. The first HYPITAT trial 1 (2009), considered non-severe hypertensive disorders of pregnancy and demonstrated that immediate delivery led to reduction in maternal morbidities, without substantially increasing risks to the baby.
Recommendations for women with non-severe hypertensive disorders at late preterm gestation (34 to 36 weeks) are much less clear; opinion has been divided regarding optimal timing of delivery 2 . The American College of Obstetrics and Gynecology recommends expectant management for women at late preterm gestations 3 . In the United Kingdom the National Institute for Health and Care Excellence recommends that women with mild or moderate pre-eclampsia at late preterm gestations should be offered delivery, "depending on maternal and fetal condition, risk factors and availability of neonatal intensive care", whereas women with gestational hypertension should not be offered delivery before 37 weeks 4 . The World Health Organisation (WHO), in recommendations for prevention and treatment of pre-eclampsia and eclampsia, suggests that expectant management may be appropriate in some women at 34 to 36 weeks with severe hypertension, providing that monitoring is available. It acknowledges that the quality of evidence on which their guidance is based is low.
This randomized trial aims to answer this question and provide some clarification. Results for the composite maternal outcome suggest that immediate delivery leads to decreased maternal morbidities; however numbers of women with the primary outcome were small and, for each individual component of the composite outcome, very small. The finding of increased rates of RDS in neonates whose mothers were delivered immediately was more convincing and overall, the results are supportive of expectant management. This is in contrast to evidence for hypertensive disorders at term. The risks of stillbirth associated with expectant management must not be underestimated; further evidence is probably needed before we can be fully confident that this is the optimal approach. The short-term neonatal outcome, RDS, was chosen, which is known to be relatively common in late preterm compared with term born infants 5,6 . However, mounting evidence suggests these infants are also at risk of long-term problems, with associations observed between pre-eclampsia and adverse neonatal outcomes and neurodevelopmental outcomes at two years of age 7, 8 . Since hypertensive disorders of pregnancy are common indications for delivery at late preterm gestations, the planned follow-up of this cohort at two and five years will be important to determine whether any long-term effects exist. Further work is also needed to elucidate whether particular antenatal diagnoses place women and their babies at greater risk than hypertension per se, but large numbers will be required to study individual diagnoses.
Until further evidence is available, it seems reasonable to employ cautious expectant management of women with non-severe hypertension at late preterm gestation to minimize adverse neonatal outcomes without increasing risks of adverse maternal outcomes.
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